EZH2 refers to Histone-lysine N-methyltransferase EZH2, which is an enzyme that in humans is encoded by the EZH2 gene. Recently, a team from the Genome Institute of Singapore and the National University of Singapore says it has found the way to target the enzyme EZH2 which puts people at risk of developing the oestrogen receptor-negative breast cancer, one of the most aggressive forms of the disease unresponsive to treatment. It has been known that EZH2 enzymatic activity promotes cancer by inactivating some important tumour suppressors, which function as ‘brakes’ to stop tumour growth. Over-expression of EZH2 is often linked to aggressive and rapid spread of breast cancers, the most common cancer in women globally.